Top Story

Elevated C-reactive protein predicts poorer outcomes in melanoma

May 4, 2015

Higher blood levels of C-reactive protein were associated with poorer OS and melanoma-specific survival in patients with invasive melanoma, according to study results.

“The relationship between changes in [C-reactive protein] and melanoma disease progression within the same patient has not been investigated,” Shenying Fang, MD, PhD, of the department of surgical oncology at The University of Texas MD Anderson Cancer Center, and colleagues wrote. “The primary aim of this study was to investigate whether increased levels of [C-reactive protein] in plasma are associated with disease stage, recurrence, or survival in patients with melanoma.”

In the Journals

Vismodegib fails to meet primary efficacy endpoints for treatment of patients with BCC

May 1, 2015
Erivedge did not meet primary efficacy endpoints of predefined histologic clearance rates in patients with basal cell carcinoma who received the treatment prior to…
Breaking NewsPerspective

FDA panel recommends approval of T-VEC for metastatic melanoma

April 29, 2015
Two FDA committees today expressed support for the approval of talimogene laherparepvec, or T-VEC, for the treatment of patients with unresectable melanoma.The Oncologic…
Howard Kaufman, MD, FACS Breaking News

FDA advisory committees consider T-VEC for metastatic melanoma

April 29, 2015
Two FDA advisory committees convened today to review Amgen’s biologic license application for its oncolytic virus, talimogene laherparepvec, as a treatment for…
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
VIDEO: Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting

VIDEO: Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting

April 26, 2015
NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of…
More »
CME
PD-1 Antibodies

PD-1 Antibodies

This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

This activity will review data on the efficacy, safety, and response patterns observed with PD-1 in patients with…
More »
In the Journals

Elevated C-reactive protein predicts poorer outcomes in melanoma

May 4, 2015
Higher blood levels of C-reactive protein were associated with poorer OS and melanoma-specific survival in patients with invasive melanoma, according…
In the Journals

Vismodegib fails to meet primary efficacy endpoints for treatment of patients with BCC

May 1, 2015
Erivedge did not meet primary efficacy endpoints of predefined histologic clearance rates in patients with basal cell carcinoma who received the…
Breaking NewsPerspective

FDA panel recommends approval of T-VEC for metastatic melanoma

April 29, 2015
Two FDA committees today expressed support for the approval of talimogene laherparepvec, or T-VEC, for the treatment of patients with unresectable…
Howard Kaufman, MD, FACS Breaking News

FDA advisory committees consider T-VEC for metastatic melanoma

April 29, 2015
Two FDA advisory committees convened today to review Amgen’s biologic license application for its oncolytic virus, talimogene laherparepvec, as…
VIDEO: Ipilimumab plus nivolumab conferred high response rates in melanoma Meeting News CoverageVideo

VIDEO: Ipilimumab plus nivolumab conferred high response rates in melanoma

April 27, 2015
F. Stephen Hodi, Jr., MD, director of the melanoma center at Dana-Farber Cancer Institute and associate professor of medicine at Harvard Medical…
VIDEO: Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting Meeting News CoverageVideo

VIDEO: Highlights from the 2015 HemOnc Today Melanoma and Cutaneous Malignancies meeting

April 26, 2015
NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of hematology and oncology at St…
Meeting News Coverage

Next-generation sequencing increases actionable mutation detection in malignant melanoma

April 26, 2015
NEW YORK — The use of next-generation sequencing in multi-gene targeted panel testing identified a considerable number of actionable mutations…
VIDEO: Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma Meeting News CoverageVideo

VIDEO: Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

April 25, 2015
NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University, presents data from patients with…
Meeting News Coverage

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015
NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene…
VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma Meeting News CoverageVideo

VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma

April 24, 2015
NEW YORK — Howard L. Kaufman, MD, FACP, associate director for clinical science at the Rutgers Cancer Institute of New Jersey, describes how…
More Headlines »